– Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined…
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage…
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage…
Montauk Brings Local Flavor to The K Korner at Citi Field with Fan-Favorite Montauk Brewing…
Montauk Brings Local Flavor to The K Korner at Citi Field with Fan-Favorite Montauk Brewing…
Virtual event on Tuesday, May 2, 2023 at 11:00am ET will feature key opinion leader…
Virtual event on Tuesday, May 2, 2023 at 11:00am ET will feature key opinion leader…
On track for initial readouts in Q2 2023 from ongoing Phase 1 VYD222 clinical trial…
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in…
On track for initial readouts in Q2 2023 from ongoing Phase 1 VYD222 clinical trial…
SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in…
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and…
SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
SAWC Spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated AC5 HCPCS…
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and…
Topline safety and clinical efficacy data from NEST-IN1 expected in the first quarter of 2024…
SAWC Spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated AC5 HCPCS…
BLOOMINGTON, Ind., April 25, 2023 (GLOBE NEWSWIRE) — Megaputer will reveal its new Insight-D™ insight…
BLOOMINGTON, Ind., April 25, 2023 (GLOBE NEWSWIRE) — Megaputer will reveal its new Insight-D™ insight…